From: Combination bronchodilator therapy in the management of chronic obstructive pulmonary disease
Therapy | LABA/LAMA | Manufacturer | Dosage | Time to onset | Trough FEV1(difference from placebo) |
---|---|---|---|---|---|
Formoterol | LABA | Mercka | Twice daily | 5 min [26] | 50–90 mL [26] |
4.5 μg (MDI) and 12 μg (DPI) | |||||
Indacaterol | LABA | Novartis | Once daily 150 and 300 μg (EU) (DPI) [20] | 5 min [22] | 130–180 mL (p < 0.001) [22] |
Indacaterol | LABA | Novartis | Once daily 75 μg (US) (DPI) [21] | 5 min [22] | |
Olodaterol | LABA | Boehringer Ingelheim | Once daily 5 and 10 μg (Respimat®) | Not available | 61–132 mL (p < 0.01) [24] |
Vilanterol | LABA | GSK | Once daily 25 and 50 μg (DPI) | Median 6 min [25] | 137–165 mL (p < 0.001) [25] |
Aclidinium | LAMA | Almirall/Forest Laboratories | Twice daily 200–400 μg (DPI) | 86–124 mL (p < 0.0001) [29] | |
Glycopyrronium | LAMA | Novartis | Once daily 50 μg (DPI) | ||
Glycopyrrolate | LAMA | Pearl Therapeutics | Twice daily 36 μg (MDI) | 5 min [19] | Statistically superior to placebo (p < 0.0001) [31] |
GSK233705 | LAMA | GSK | Twice daily 200 μg | Not available | 130 mL (p < 0.001) [32] |
Tiotropium | LAMA | Boehringer Ingelheim | Once daily 18 μg (DPI) and 5 μg (via SMI) | 15 min [18] | 120–150 mL (p < 0.001) [18] |
Umeclidinium (GSK573719) | LAMA | GSK | Once daily | Not available | Not available |